Kasper Roet

Founder at QurAlis Corp.

Health Technology

Profile

Kasper Roet founded QurAlis Corp., where he worked as Chief Executive Officer & Director and Enclear Therapies, Inc., where he worked as Director.

Kasper Roet active positions

Companies	Position	Start
QurAlis Corp. QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.	Founder	-
Enclear Therapies, Inc. Enclear Therapies, Inc. Pharmaceuticals: MajorHealth Technology Enclear Therapies, Inc. develops and manufactures novel device-based therapies to treat patients. The firm device is developed to treat and halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The company was founded by Anthony R. DePasqua, Jonathan J. Fleming, Kasper Roet, William B. Gormley and Kevin Eggan and is headquartered in Newburyport, MA.	Founder	-

All active positions of Kasper Roet

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kasper Roet's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
QurAlis Corp. QurAlis Corp. Pharmaceuticals: MajorHealth Technology QurAlis Corp. engages in discovering and developing new therapies for amyotrophic lateral sclerosis and other neurological diseases. It offers therapeutic programs and targets, and biomarkers. The company was founded by Clifford Woolf, Kevin Eggan, Jonathan J. Fleming, and Kasper Roet and is headquartered in North Cambridge, MA.	Health Technology
Enclear Therapies, Inc. Enclear Therapies, Inc. Pharmaceuticals: MajorHealth Technology Enclear Therapies, Inc. develops and manufactures novel device-based therapies to treat patients. The firm device is developed to treat and halt the progression of neurodegenerative diseases by removing toxic proteins known to drive pathology. The company was founded by Anthony R. DePasqua, Jonathan J. Fleming, Kasper Roet, William B. Gormley and Kevin Eggan and is headquartered in Newburyport, MA.	Health Technology